Relaxin-3 receptor (Rxfp3) gene deletion reduces operant sucrose-but not alcohol-responding in mice

AW Walker; CM Smith; AL Gundlach; AJ Lawrence

Journal article

Relaxin-3 receptor (Rxfp3) gene deletion reduces operant sucrose-but not alcohol-responding in mice

AW Walker, CM Smith, AL Gundlach, AJ Lawrence

Genes, Brain and Behavior | WILEY-BLACKWELL | Published : 2015

DOI: 10.1111/gbb.12239

University of Melbourne Researchers

Andrew Gundlach Author Anatomy and Neuroscience

Andrew Lawrence Author Florey Department of Neuroscience and Mental Health

Related Projects (4)

Neural control of behavioural state in health and disease

Our research aims to describe and understand newly identified nerve pathways or 'networks' in brain that control physiological homeostasis o..

A NEW THERAPEUTIC TARGET FOR STRESS-RELATED RELAPSE

Relapse and hazardous drinking represent the most difficult clinical problems in treating patients with alcohol use disorders. We have ident..

RESEARCH FELLOWSHIP

I am a neuroscientist, studying fundamental mechanisms related to addiction. A major feature of my research is the neuropharmacological char..

How the brain regulates reward

Substance abuse is a significant social and economic burden upon Australian societies and on societies around the world. Treatment remains p..

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia

Funding Acknowledgements

This research was supported by National Health and Medical Research Council (NHMRC) of Australia project grants (1021227 and 1079893 to A.J.L. and A.L.G.) and Research Fellowships (1020737 and 1005985) to A.J.L. and ALG; a grant from the Pratt and Besen Foundations and the Victorian Government's Operational Infrastructure Support Program. A.W.W. was the recipient of University of Melbourne International Postgraduate Research Scholarships (APA/IPRS). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors thank Dr Timothy Lovenberg (Neuroscience Drug Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson) for commissioning the production of the Rxfp3 KO strain and providing the Florey Institute of Neuroscience and Mental Health (A.L.G.) with an original breeding colony.